Appili Therapeutics (APLIF) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free APLIF Stock Alerts $0.03 0.00 (0.00%) (As of 05/22/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 21 at 1:22 AM | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) vs. Appili Therapeutics (OTCMKTS:APLIF) Critical ContrastMay 14, 2024 | americanbankingnews.comShort Interest in Appili Therapeutics Inc. (OTCMKTS:APLIF) Drops By 16.3%April 27, 2024 | finanznachrichten.deAppili Therapeutics Inc.: Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.April 26, 2024 | finance.yahoo.comAppili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.April 26, 2024 | globenewswire.comAppili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.April 18, 2024 | finance.yahoo.comAppili Therapeutics Inc. (APLIF)April 4, 2024 | uk.investing.comAditxt to acquire Appili Therapeutics in strategic moveApril 2, 2024 | businesswire.comAditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)April 2, 2024 | finance.yahoo.comAppili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.April 2, 2024 | globenewswire.comAppili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.March 12, 2024 | globenewswire.comResearchers Publish Manuscript on the Prevention and Emergency Response to Tularemia OutbreaksFebruary 14, 2024 | finanznachrichten.deAppili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024February 14, 2024 | seekingalpha.comAppili Therapeutics reports Q3 resultsFebruary 13, 2024 | finance.yahoo.comAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024February 13, 2024 | globenewswire.comAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024February 3, 2024 | morningstar.comAppili Therapeutics Inc Ordinary SharesDecember 6, 2023 | finance.yahoo.comAPLIF: ATI-1701 Program Awarded Additional US$6.6 Million in Funding…November 14, 2023 | msn.comAppili Therapeutics GAAP EPS of -C$0.01November 13, 2023 | finance.yahoo.comAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024October 25, 2023 | finance.yahoo.comAppili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force AcademyOctober 5, 2023 | finance.yahoo.comAPLIF: FDA Approves LIKMEZ™ (ATI-1501)…September 27, 2023 | ca.finance.yahoo.comUPDATE 2-Canada's Appili gets US FDA approval for oral antibiotic solutionSeptember 27, 2023 | finance.yahoo.comAppili Therapeutics Presents at the 10th International Tularemia ConferenceSeptember 25, 2023 | marketwatch.comAppili Therapeutics' Licensing Partner Gets FDA Approval for Metronidazole Oral SuspensionSeptember 25, 2023 | stockhouse.comAppili Therapeutics Announces U.S. FDA Approval of LIKMEZ(TM) (ATI-1501) Metronidazole Oral SuspensionSeptember 25, 2023 | markets.businessinsider.comAppili Therapeutics Says FDA Approves LIKMEZ Metronidazole Oral SuspensionSeptember 25, 2023 | finance.yahoo.comAppili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral SuspensionSeptember 25, 2023 | finance.yahoo.comUPDATE 1-Canada's Appili gets US FDA approval for oral antibiotic solutionJuly 17, 2023 | finance.yahoo.comAPLIF: Executes Initial Contract with USAFA for Development of ATI-1701…June 29, 2023 | finance.yahoo.comAppili Therapeutics Announces Bridge Loan from Bloom Burton & Co.June 28, 2023 | finance.yahoo.comAppili Therapeutics Full Year 2023 Earnings: CA$0.081 loss per share (vs CA$0.38 loss in FY 2022)June 23, 2023 | seekingalpha.comAppili Therapeutics GAAP EPS of -C$0.08June 23, 2023 | finance.yahoo.comAppili Therapeutics Reports Fiscal Year 2023 Financial and Operational ResultsMay 24, 2023 | finance.yahoo.comAppili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of MetronidazoleMay 8, 2023 | finance.yahoo.comAppili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force AcademyApril 18, 2023 | finance.yahoo.comAppili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 3, 2023 | finance.yahoo.comAppili Therapeutics Appoints Dr. Gary Nabors as Chief Development OfficerMarch 20, 2023 | finance.yahoo.comAppili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone HoldingsFebruary 21, 2023 | finance.yahoo.comAPLIF: FDA Accepts NDA for ATI-1501; PDUFA Date for September 23, 2023…February 16, 2023 | seekingalpha.comAPLI:CA Appili Therapeutics Inc.February 14, 2023 | businesswire.comAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023February 8, 2023 | finance.yahoo.comAppili Therapeutics Announces that FDA accepts the ATI-1501 NDAJanuary 17, 2023 | financialpost.comAppili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine ProgramJanuary 13, 2023 | finance.yahoo.comAppili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of MetronidazoleNovember 16, 2022 | finance.yahoo.comAPLIF: Reprioritizing Resources to Focus on ATI-1701, ATI-1801, and ATI-1501…November 14, 2022 | finance.yahoo.comAppili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force AcademyNovember 10, 2022 | finance.yahoo.comAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023September 22, 2022 | finance.yahoo.comAppili Therapeutics Announces Results of Annual and Special Meeting of ShareholdersAugust 12, 2022 | finance.yahoo.comAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023August 2, 2022 | finance.yahoo.comAppili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia Get Appili Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLIF and its competitors with MarketBeat's FREE daily newsletter. Email Address Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything. Discover the #1 company leading this revolution APLIF Media Mentions By Week APLIF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLIF News Sentiment▼-0.710.43▲Average Medical News Sentiment APLIF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLIF Articles This Week▼10▲APLIF Articles Average Week Get Appili Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLIF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NBY News REVB News ARDS News ARAV News PHIO News CWBR News BPTS News LGVN News MBIO News VRPX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:APLIF) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…StocksToTradeThis could mean the end of the U.S dollar…Colonial MetalsThe 1,000X Crypto PlaybookTrue Market InsidersGold Set to EXPLODE!Gold Safe Exchange[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaAlex’s “Next Magnificent Seven” stocksThe Oxford ClubNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Appili Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
